아타라 바이오테라피즈(ATRA) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 아타라 바이오테라피즈(ATRA)?

아타라 바이오테라피즈(ATRA) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of ATRA?

The market cap of ATRA is approximately $69M, ranking 4,759 within its sector.

Q: What is the 52-week high and low for ATRA?

ATRA has recorded a 52-week high of $19.15 and a low of $3.92.

ATRA

Atara Biotherapeutics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$7.71

-0.19 ▼ -2.41%

아타라 바이오테라피즈(ATRA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$69M

스몰캡

P/E

배당수익률

없음

52주 위치

25%

저점 +97% · 고점 -60%

애널리스트

매수

Fundamental health

vs. Biotechnology· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 70%

밸류에이션

Top 83%

재무 안정

Top 45%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.88	Insider Own ⓘ	33.4%	Shs Outstand ⓘ	8.5M	Perf Week ⓘ	-7%
Market Cap ⓘ	0.07B	Forward P/E ⓘ	8.61	EPS next Y ⓘ	169.11%	Insider Trans ⓘ	6.41%	Shs Float ⓘ	6.0M	Perf Month ⓘ	-24.56%
Enterprise Value ⓘ	0.11B	PEG ⓘ	-	EPS next Q ⓘ	-0.32	Inst Own ⓘ	48.4%	Short Float ⓘ	9.63%	Perf Quarter ⓘ	53.89%
Income ⓘ	-0.01B	P/S ⓘ	3	EPS this Y ⓘ	-150.39%	Inst Trans ⓘ	1.03%	Short Ratio ⓘ	0.4	Perf Half Y ⓘ	47.7%
Sales ⓘ	0.02B	P/B ⓘ	-	EPS next 5Y ⓘ	-	ROA ⓘ	-23.08%	Short Interest ⓘ	0.58M	Perf YTD ⓘ	-57.38%
Book/sh ⓘ	-4.38	P/C ⓘ	8.31	EPS past 3/5Y ⓘ	-	ROE ⓘ	-	52W High ⓘ	-59.73% ($19.15)	Perf Year ⓘ	-33.42%
Cash/sh ⓘ	0.93	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	23.85% -	ROIC ⓘ	-75.6%	52W Low ⓘ	96.68% ($3.92)	Perf 3Y ⓘ	-82.77%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	76.14%	Gross Margin ⓘ	96.12%	Volatility(W/M) ⓘ	7.6% 7.84%	Perf 5Y ⓘ	-97.55%
Dividend TTM ⓘ	-	EV/Sales ⓘ	4.87	Sales Y/Y TTM ⓘ	-88.41%	Oper. Margin ⓘ	-26.42%	ATR (14) ⓘ	0.73	Perf 10Y ⓘ	-98.71%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	2.16	EPS Q/Q ⓘ	-108.4%	Profit Margin ⓘ	-40.91%	RSI (14) ⓘ	35.77	Recom ⓘ	1.67
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	2.16	Sales Q/Q ⓘ	-99.47%	SMA20 ⓘ	-17.7% ($9.37)	Beta ⓘ	0.16	Target Price ⓘ	$13.67
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/5/12	SMA50 ⓘ	-21.01% ($9.76)	Rel Volume ⓘ	0.04	Prev Close ⓘ	$7.9
Employees ⓘ	14	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	11.99% -82.21%	SMA200 ⓘ	-19.43% ($9.57)	Avg Volume(3M) ⓘ	1.43M	Price ⓘ	$7.71
IPO ⓘ	2014/10/16	Option/Short ⓘ	No/Yes			Trades ⓘ	663	Volume ⓘ	62,731	Change ⓘ	-2.41%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $1M (YoY -99%) · 순이익 $-4M (YoY -111%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Atara Biotherapeutics Inc (ATRA) Investment Analysis

What kind of company is Atara Biotherapeutics Inc?

아타라 바이오테라피즈(ATRA) 방어주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🧬 Atara Biotherapeutics (ATRA) is a US biotech company developing allogeneic (donor-derived) T-cell-based cell therapies. Through its off-the-shelf treatment candidates using donor-derived immune cells, the company targets post-transplant viral-associated diseases and immune disorders. It is classified as a clinical-stage, research and development-focused company.

Learn more about Atara Biotherapeutics Inc →

Market Cap

$0.1B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4759

Employees14people

IPO2014/10/16

Current Price$7.71 ≈ 10,563원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 12일 (화) · 장 마감 후 EPS +12.0% 매출 -82.2%

🔔 Earnings release 2026년 3월 16일 (월) · 장 마감 후 EPS -42.1% 매출 -51.2%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-26.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-40.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

96.1%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Top 10%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROA

Annual earnings relative to total company assets

-23.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-75.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

2.16

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.16

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$13.67

현재가 대비 +77.3%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

8.61배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+169.1%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

-113.4%

평균 서프라이즈

2026.05.12

상회

+12.0%

2026.03.16

하회

실적 $-0.35 · 예상 $-0.10 -238.7%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-150.4%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 초소형주 Median 21.2% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+169.1%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median 14.5% · Top 11%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-99.5%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 초소형주 Median -4.5% · Bottom tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -166%p below the market

ATRA -97.5% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-165.9%p

Significantly behind the market

vs Health Care (XLV)

-122.0%p

Significantly behind the sector average

1-year basis

vs S&P 500

-49.4%p

Significantly behind the market

vs Health Care (XLV)

-53.1%p

Significantly behind the sector average

Rank among peers

5-year return Lower-Mid (lower 41%) Based on 245 peers

1-year return Upper-Mid (41%) Based on 315 peers

Current position within 52-week range

Low (-96.7%p) High (-59.7%p)

Current price is 96.7% above the 52-week low and 59.7% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-37.4%

Annualized volatility

134.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $7.71 below the midline ($9.37). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.550 < Signal -0.360 in negative zone + Hist negative (-0.191). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 35.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 2.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🧾 Vs. Sales Cheap

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

8.61x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology median 20.98x · Top 11% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

3.00x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 median 11.24x · Top 23% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$13.67 vs. current price +77.3%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership flow is positive

Insider modest net buying +6.4% · Institutional net buying +1.0% · Short interest moderate 9.6% · Short interest up +1.9pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+6.4%

Insiders net buying

🏦 Institutions (funds & investors)

+1.0%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 48.4%

Moderate institutional participation

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 33.4%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 18.2%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

9.6%

Moderate

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +1.9%p increase

Short interest days to cover

0.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 8.5M주

Float (tradable shares) 6.0M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ATRA

ETFs with the highest weightings · 6 total shown

DCOR

Dimensional US Core Equity 1 ETF

0.00%

$3.3B

DFAC

Dimensional U.S. Core Equity 2 ETF

0.00%

$47.5B

DFAS

Dimensional U.S. Small Cap ETF

0.00%

$15.2B

IWC

iShares Micro-Cap ETF

0.00%

$1.4B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ATRA This Stock	$69.5M	-	-	-	-	-2.4%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 아타라 바이오테라피즈(ATRA)?

아타라 바이오테라피즈(ATRA) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ATRA?

The market cap of ATRA is approximately $69M, ranking 4,759 within its sector.

What is the 52-week high and low for ATRA?

ATRA has recorded a 52-week high of $19.15 and a low of $3.92.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.